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Research
30%–40% of patients do not receive evi-
dence-based care, while in 20% of patients
care may be not needed or potentially harm-
ful.1 However, relatively little information
exists about how to apply evidence in clinical
practice, and data on the effect of evidence-







Objective:  To evaluate the outcomes of and barriers to implementing standard 
guidelines (Caring for Australasians with renal impairment [CARI]), using iron 
management in patients having dialysis as an example.
Design and setting:  On-site review of iron management processes at six Australian 
sis units varying in size and locality. Patients’ iron indices and haemoglobin levels 
 obtained from the Australian and New Zealand Dialysis and Transplant Registry.
cipants:  Patients with chronic kidney disease who were dependent on dialysis.
 outcome measures:  Processes for assessing indices of iron stores and iron 
lementation; comparison with target indices in the CARI guidelines.
lts:  There was considerable variability among the units in achievement of 
haemoglobin and iron targets, with 25%–32% of patients achieving haemoglobin targets 
of 110–120 g/L, 30%–68% achieving ferritin targets of 300–800 μg/L, and 65%–73% 
achieving transferrin saturation targets of 20%–50%. Implementation barriers included 
lack of knowledge, lack of awareness of or trust in the CARI guideline, inability to 
implement the guideline, and inability to agree on a uniform unit protocol. Factors 
associated with achieving the CARI guideline targets included nurse-driven iron 
management protocols, use of an iron management decision aid, fewer nephrologists 
per dialysis unit, and a “proactive” (actively keeping iron levels within target range) 
rather than “reactive” (only reacting if iron levels are out of the range) protocol.
Conclusions:  Variability in achievement of iron targets, despite the availability of a 
clinical practice guideline, may be explained by variability in processes of care for 
MJA 2006; 185: 310–314
achieving and maintaining adequate iron parameters.
For editorial comment, see page 301tud
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haS ies examining the link betweenearch evidence and clinical practiceve consistently shown gaps between
the evidence and current practice. Some
studies in the United States suggest that
ess of care or patient outcomes is limited.
In Australia and New Zealand, national
guidelines for treating patients with chronic
kidney disease — the Caring for Australasi-
ans with renal impairment (CARI)
guidelines2 — were published and dissemi-
nated to nephrologists in March 2000, with
details and updates on the CARI website
(http://www.cari.org.au). They provide
nephrologists, renal nurses and other health
carers with an evidence base for patient
management and improving outcomes.
The focus of one of the CARI guidelines2 is
anaemia, a common complication of chronic
kidney disease. Management of iron levels in
patients with chronic kidney disease involves
both excluding iron deficiency in uraemic–
anaemic patients, and providing adequate
iron stores to allow patients to efficiently
maintain target haemoglobin concentrations,
especially with the concomitant use of sup-
plementary erythropoietin proteins (epoetin).
Failure to achieve adequate iron stores and
availability is the major cause of epoetin
resistance, which may result in increased
costs to correct the anaemia.3 In observa-
tional studies of haemodialysis patients, it has
been shown that the relative risk of death and
hospitalisation increases significantly with
haemoglobin levels below the target.4
In an effort to understand the impact of
guidelines, our study was designed to evaluate
the outcomes of a standard implementation
strategy (passive dissemination of guidelines
in hardcopy form and on the Internet) of the
CARI guidelines using an example — iron
management of dialysis patients in Australia.
In assessing this strategy, we sought to identify
barriers to guideline implementation5-7 using
a “process of care” approach, with a view to
developing strategies to increase uptake of
evidence into practice. We hope that lessons




From the CARI guidelines biochemical and
haematological targets,2 the guideline for
iron was chosen for this study because:
• it has high levels of supporting evidence;
• it is of clinical relevance to all renal units;
• there are potentially high costs associated
with not applying this guideline (related to
greater epoetin product use); and
• it involves easily measured parameters,
and the necessary data are collected by the
Australian and New Zealand Dialysis and
Transplant Registry (ANZDATA; <http://
www.anzdata.org.au>).8
The evolution of the evidence base has led
to changes in target levels. Initially, the CARI
guidelines (March 2000) set a target mini-
mum haemoglobin level of 120 g/L for
patients having dialysis for chronic kidney
disease. The current revised minimum hae-
moglobin target level is 110 g/L, but, as
previously, the level should not exceed
120 g/L for patients with diabetes or estab-
lished additional cardiovascular risk.2 For
patients having dialysis, the target ranges of
iron values are: serum ferritin level, 300–
800 μg/L; and transferrin saturation (TSAT),
20%–50%, and/or percentage of hypochro-
mic red blood cells < 2.5%.
Renal unit data
A review of iron management processes in six
renal units in New South Wales, Victoria and
the Australian Capital Territory was performed
in September 2004. All units approached gave
consent for staff to be interviewed on the
process of iron management in both peritoneal
dialysis and haemodialysis (in-centre, satellite
and home dialysis patients).A • Volume 185 Number 6 • 18 September 2006
RESEARCHEach dialysis unit received an on-site visit.
Fifteen staff from the six units were inter-
viewed, with the number interviewed  at
each unit being determined by the size and
configuration of the unit. Nursing and med-
ical staff were given a standardised inter-
viewer-completed questionnaire about the
details of their unit’s iron protocols, and the
processes for managing anaemia.
From each unit, we retrieved copies of
anaemia and iron-related documentation
(iron management policies and procedures,
blank or de-identified patient medication
charts, nursing care plans, intravenous iron
standing orders, and administration proto-
cols). The local process for iron manage-
ment was mapped and reported for each
unit. On completion, reports were returned
to unit staff for ratification before analysis.
Data tabulated for each unit included the
different protocols (compared with the
CARI guideline), whether a protocol was
followed, and a comparison of unit proto-
cols and practices for target iron parameters
and thresholds for prescribing or withhold-
ing intravenous iron.
Demographic characteristics and iron-
related data
ANZDATA records incidence, prevalence
and outcome data for all patients treated for
end-stage kidney disease. Relevant to the
current study, ANZDATA also routinely col-
lects demographic, haematological and bio-
chemical data, type of dialysis, dialysis
prescription, and complications and death
rates.8 For our review, with specific permis-
sion from the Units concerned, de-identified
data on patients’ haemoglobin levels and the
results of iron studies (serum ferritin and
TSAT), as well as demographic characteris-
tics, were released by ANZDATA. These data
were from the March 2004 ANZDATA sur-
vey, and the iron studies were the most
recent for each patient before that date.
Statistical analysis
Renal units were compared descriptively
using percentages for qualitative parame-
ters (eg, patients’ sex) and using medians
and interquartile range for quantitative
1 Demographic characteristics, iron scores and dialysis details of patients at six renal units





No. (%) patients 115 (6%) 296 (17%) 322 (18%) 428 (24%) 413 (23%) 189 (11%) 1763 (100%) 7699
Sex 0.3 0.001
No. (%) males 66 (57%) 190 (64%) 183 (57%) 273 (64%) 257 (62%) 117 (62%) 1086 (61%) 4465 (58%)
No. (%) females 49 (43%) 106 (36%) 139 (43%) 155 (36%) 156 (38%) 72 (38%) 677 (39%) 3234 (42%)
Age in years, median (IQR) 70 (19) 60.5 (25) 59 (22) 63 (21) 61 (26) 61 (22) < 0.001 62 (23) 63 (23) < 0.001
No. (%) Indigenous§ 54 (3%) 760 (10%) < 0.001
No. (%) non-Indigenous 1709 (97%) 6939 (90%)
Iron scores, median (IQR)
Haemoglobin (g/L) 120 (22) 119 (23) 112 (22) 116 (20) 121 (21) 118 (22) < 0.001 118 (21) 118 (21) 0.36
Ferritin (μg/L) 309 (200) 165 (290) 163 (225) 348 (316) 393 (279) 501 (401) < 0.001 319 (353) 386 (432) < 0.001
TSAT (%) —¶ 25% (16%) 25% (14%) 25% (13%) 29% (16%) 23% (13%) < 0.001 26% (15%) 26% (15%) 0.88
Dialysis
Type of dialysis, no. (%) patients < 0.001 < 0.001
Hospital haemodialysis 44 (38%) 61 (21%) 16 (5%) 30 (7%) 38 (9%) 30 (16%) 219 (12%) 2080 (27%)
Satellite haemodialysis 32 (28%) 79 (27%) 80 (25%) 223 (52%) 224 (54%) 77 (41%) 715 (41%) 3063 (40%)
Home haemodialysis 20 (17%) 86 (29%) 78 (24%) 73 (17%) 35 (9%) 23 (12%) 315 (18%) 776 (10%)
Peritoneal dialysis** 19 (16%) 70 (24%) 148 (46%) 102 (24%) 116 (29%) 59 (31%) 514 (29%) 1780 (23%)
Taking epoetin, no. (%) patients < 0.001 < 0.001
Yes 109 (95%) 261 (88%) 271 (84%) 386 (90%) 356 (86%) 147 (78%) 1530 (87%) 6930 (90%)
No 6 (5%) 35 (12%) 51 (16%) 42 (10%) 57 (14%) 42 (22%) 233 (13%) 769 (10%)
Duration of dialysis in years, 
median (IQR) 
4 (4.4) 3.5 (5.0) 4 (4.6) 3.5 (4.3) 3.8 (4.5) 4 (5.0) 0.6 3.5 (5.2) 2.8 (4.3) < 0.001
IQR = interquartile range; TSAT = transferrin saturation.
* χ2 test or Kruskal–Wallis test used for univariate analysis among units.
† Units represented: The Canberra Hospital, ACT; Central Coast Area Health Service, NSW (Gosford Hospital); Central Sydney Area Health Service, NSW (Royal Prince 
Alfred Hospital, Concord Hospital and the Dame Edith Walker Centre); Monash Medical Centre, Vic; Royal Melbourne Hospital, Vic; and Sydney West Area Health 
Service, NSW (Westmead Hospital and Blacktown Hospital).
‡ χ2 test or two-sample Wilcoxon rank-sum (Mann–Whitney) test used for analysis between all units and Australian dialysis population data.
§ Numbers for all units combined given, as individual unit numbers for Indigenous patients were too small.
¶ Unit 1 does not routinely test for TSAT, but for percentage of hypochromic red blood cells, and these data are not available through the Australian and New Zealand 
Dialysis and Transplant Registry.
** Peritoneal dialysis includes continuous ambulatory peritoneal dialysis, automated peritoneal dialysis and intermittent cycler peritoneal dialysis. ◆MJA • Volume 185 Number 6 • 18 September 2006 311
RESEARCHparameters (eg, iron parameters, age, dura-
tion of dialysis). We used χ2 tests for
proportions, and Kruskal–Wallis or Mann–
Whitney tests for quantitative parameters.
A non-parametric approach was necessary
for quantitative parameters because of the
skewed distribution of some parameters;
for consistency, this approach was adopted
for the analysis of all quantitative parame-
ters. Statistical analysis was completed
using SPSS software, version 11.5.1 (SPSS
Inc, Chicago, Ill, USA).
RESULTS
There were 1763 patients in the dataset
from the six units (Box 1). Statistically
significant differences were found between
m e d i a n  v a l u e s  f o r  h a e m o g l o b i n
(P < 0.001), ferritin (P < 0.001) and TSAT
levels (P < 0.001). Among the units,
patients’ median haemoglobin levels
ranged from 112 g/L to 121 g/L, median
ferritin levels from 163 μg/L to 501 μg/L,
and median TSAT percentages varied from
23% to 29%.
Box 2 shows the proportion of patients
who were within or outside CARI target iron
parameters for each unit. The proportions
were significantly different across the units.
The greatest difference was in ferritin levels
in Unit 3 compared with Unit 5, with 26%
versus 68% of patients in the target range,
respectively.
Box 3 shows the process pathway for iron
management across the units. Each unit
varied each of the steps depending on local
protocols. Practices differed widely from the
CARI guideline and between the units. Most
units agreed with the CARI guideline on the
lower margin of the range for iron stores,
but there was a tendency for all units in their
local adaptation of the guideline to adopt a
lower level for the upper limit for iron
stores. Units also varied widely in the fre-
quency with which iron studies were under-
taken, as well as whether oral or intravenous
iron therapy was administered and what
dosages were used.
The process for iron management was dif-
ferent for each unit. All units had a written
iron protocol, but not all units complied with
their protocol. Units 1, 5 and 6 had a written,
agreed and implemented protocol. Units 1
and 5 had a standing order for iron that
allowed nursing staff to administer iron
within this specified protocol. Units 1, 5 and
6 had a decision aid for administering iron.
Many variables affected the iron management
process. A summary of each unit’s iron man-
agement process is given in Box 4.
The possible barriers to more successful
implementation of the guideline, which
were identified from the results of the review
of the six units, are listed in Box 5.
Each staff member interviewed was aware
of the CARI guidelines and the iron guide-
line disseminated in March 2000. Not all
were aware that the website carries updates.
DISCUSSION
Passive dissemination of the CARI guide-
lines in March 2000 resulted in awareness of
the iron guideline, but we found significant
variation in implementation of the guideline
across the six dialysis units examined. All
units had an iron management process in
place; however, the variability of the levels
achieved for the iron indices is a measure of
the effectiveness of the process. An effective
process seems to depend on the strength of a
unit’s local protocol and the staff available to
drive the protocol processes.
Every step in the iron management clini-
cal process pathway (Box 3) contains factors
influencing iron management. Identifying
strengths and weaknesses in this process for
3 Clinical pathway for iron management in patients with renal impairment
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RESEARCHindividual units will aid implementation. As
our study is primarily a qualitative study,
drawing statistical inferences is difficult.
However, there appears to be a link between
achieving higher ferritin concentrations and
autonomy given to nursing staff to manage
patients’ iron levels under an agreed proto-
col. Other factors that appear to influence
guideline adherence and patient outcomes
are:
• agreement between nursing staff and
nephrologists on a protocol for the unit;
• using an effective decision aid (Box 6);
• the number of nephrologists practising in
a particular unit (negative effect with
increasing numbers);
• the degree of physician reliance on a
protocol being actively implemented; and
• the iron management protocol being
“proactive” rather than “reactive”. Evidence
suggests that a proactive or maintenance-
dosing iron therapy regimen is superior to a
reactive regimen (ie, only prescribing iron
therapy when iron indices are outside the
defined ranges).3,9,10
Some dialysis facilities had lower target
haemoglobin concentrations and lower
achieved levels, possibly due to concerns
about increased thrombotic risk and mortal-
ity rates. These concerns were raised by the
publication of a randomised controlled trial
linking an increase in mortality to high
haemoglobin concentrations in haemodialy-
sis patients with symptomatic heart fail-
ure.11 Another barrier to aggressive iron
administration is a reluctance on the part of
nephrologists to allow ferritin levels to
become “too high”. Although all agreed that
the lower limit for ferritin should be
> 300 μg/L, some believed that the CARI
guideline upper limit of 800 μg/L was too
high and exposed patients to the risk of iron
toxicity (ie, increased risk of infection, oxi-
dative stress,12 and impaired neutrophil
function).13 Some dialysis units subse-
quently adopted a revised local protocol,
lowering target ferritin concentrations to
differing extents. This change in practice is
reflected in the new evidence-based CARI
guideline published in April 2006 in which
the upper limit for ferritin has been reduced
to 500 μg/L.14
A potential limitation of our study is the
small number of dialysis units surveyed.
However, the patients in the six units
involved were a 23% sample of the Austral-
ian dialysis population (March 2004), and
care was taken to ensure they were generally
representative of the population of patients
with chronic kidney disease having dialysis.
We included a range of units with different
practices and iron indices, and our data
show substantial variability, which we
sought to explain.
The sample had a lower proportion of
Aboriginal and Torres Strait Islander
patients compared with the overall Austral-
ian dialysis population. Indigenous patients
have been reported to have lower ferritin
and TSAT values than non-Indigenous
patients, and may require different iron
management processes.15 Further research
into the needs of Indigenous patients having
dialysis is required to determine their partic-
ular requirements and the applicability of
the CARI guideline to Indigenous patients.
There is a growing body of research on
how evidence is taken up into clinical prac-
tice. The most common strategies in use —
continuing medical education and passive
dissemination of guidelines — have consist-
ently been shown to have very little impact
on practice patterns or improving patient
outcomes.7,16-19 For successful implementa-
tion of guidelines, it is necessary to devise a
strategy or plan for the project.6-8 The first
task is to understand the local setting for
implementation and the target group,20 as
well as the current process or clinical path-
way that needs to be altered (Box 3). Under-
standing each step in the clinical pathway
and how individual units move through
these stages will reveal the barriers to
change for those units,5-7,20 and a multifac-
eted implementation plan can be devised to
overcome these barriers.16,19-21
In our study, identification of barriers was
made at seven different levels of the organi-
sation, using the National Institute for Clin-
ical Studies barrier tool.22 Box 5 shows the
many possible barriers at all units, involving
nephrologists, renal nurses, patients, and
issues at a unit level, management level or
infrastructure level, as well as the guideline
5 Possible barriers to successful 
implementation of the iron guideline
Nephrologist
• Lack of awareness or knowledge of a 
guideline
• Lack of knowledge regarding iron 
requirements
• Lack of “trust” in the guideline
• Lack of ability to implement the guideline 
in own practice
Renal nurse
• Lack of awareness or knowledge of 
guideline
• Lack of knowledge regarding iron 
requirements
• Has to follow/wait for instruction from 
nephrologist regarding iron management
• Possible increased workload
• Following up home dialysis patients
Patient
• Not accepting iron as important
• Side effects from prescribed treatments
• Comorbid conditions may take 
precedence
• May be a home dialysis patient
Unit level issues
• Large numbers of nephrologists working 
within the one dialysis unit
• Lack of agreement on iron targets among 
nephrologists
• Lack of effective iron protocol available for 
staff to follow
• Lack of care plan available for staff to 
follow for iron management
Management issues
• May not realise that iron management is 
an issue
• Unaware of the reduction in relative cost 
of anaemia management with epoetin, by 
provision of adequate iron
Infrastructure issues
• Increased nursing time to check 
laboratory results of iron studies
• Lack of computerised results
• Laboratories do not automatically send 
blood test results to dialysis units; nurses are 
required to access results for their patients
• Iron measurements come from a range of 
laboratories with different ordering 
processes and accessibility of results
Guideline
• Lack of evidence for dosage requirements 
for iron management ◆
4 Summary of each dialysis unit’s 
iron management processes
Unit Summary of process
1 Small unit, single nephrologist, nurse-
driven standing order, proactive iron 
regimen
2 Large unit, no agreed protocol, 
reactive iron regimen
3 Protocol available but not used, 
reactive iron regimen
4 Physician-reliant protocol, effective 
decision aid, reactive iron regimen
5 Agreed protocol, decision aid, nurse-
driven standing order, proactive iron 
regimen
6 Agreed protocol, computerised 
decision aid, proactive iron regimen ◆MJA • Volume 185 Number 6 • 18 September 2006 313
RESEARCHitself. Individual units wanting to imple-
ment the iron guideline can identify which
barriers may be applicable to them and
devise strategies to overcome these. Once
these barriers have been overcome, regular
audits are needed to ensure that the per-
formance indicators have improved (ie, the
proportion of patients achieving targets has
increased). This completes the quality cycle,
ensuring ongoing delivery of optimal evi-
dence-based care.
Research into effective methods for imple-
menting clinical practice guidelines lags
behind the research methods involved in
producing guidelines. Our study highlights
the possible barriers to implementing the
CARI guideline for iron. To truly gain an
understanding of which guideline imple-
mentation methods are most successful,
controlled-intervention observational stud-
ies and completion of the quality cycle, with
critical review of the achievement of targets,
should be undertaken in renal medicine.
Passive dissemination of the CARI iron
guideline (our example) raised awareness of
the guideline, but improving iron manage-
ment and patient outcomes will take com-
mitment to change within the renal care
team, an agreed iron protocol with a deci-
sion support aid, a working process for iron
management, and skills improvement for
renal nursing staff. Factors affecting iron
management and barriers to change are
numerous. For successful guideline imple-
mentation, a strategy to overcome these
barriers in individual units should be
planned and executed.
This example can be adapted to other
clinical settings across a range of medical
disciplines. Successful implementation of
clinical practice guidelines is not achieved
by forcing physicians to obey “rules”, but
rather by creating an environment in which
they are given the skills, knowledge, atti-
tudes and support systems to help them
provide their patients with the best possible
care, based on the best possible evidence.
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6 Iron management decision aid 





Dose of iron 
polymaltose Frequency
< 300 < 50% 100 mg Weekly*




> 650 < 20% Nil† Nil‡
> 650 > 20% Nil† Nil
* If patient is taking a weekly dose, withhold iron the 
week before repeating iron studies every second 
month.
† Withhold iron infusions for 2 months, then repeat 
iron studies.
‡ Withhold iron infusions for 2 months, and 
commence oral vitamin C 250 mg three times a 
week. TSAT = transferrin saturation. ◆314 MJA • Volume 185 Number 6 • 18 September 2006
